Breaking News Instant updates and real-time market news.

OPK

Opko Health

$2.03

(0.00%)

, TXMD

TherapeuticsMD

$2.64

(0.00%)

09:40
06/21/19
06/21
09:40
06/21/19
09:40

Unusually active option classes on open June 21st

Unusual total active option classes on open include: Opko Health (OPK), TherapeuticsMD (TXMD), Barrick Gold (GOLD), Canopy Growth (CGC), Oracle (ORCL), Lululemon (LULU), PG&E (PCG), Beyond Meat (BYND), Aurora Cannabis (ACB), and Schlumberger (SLB).

OPK

Opko Health

$2.03

(0.00%)

TXMD

TherapeuticsMD

$2.64

(0.00%)

GOLD

Barrick Gold

$15.32

(0.00%)

CGC

Canopy Growth

$43.70

(0.00%)

ORCL

Oracle

$57.02

(0.00%)

LULU

Lululemon

$186.33

(0.00%)

PCG

PG&E

$23.59

(0.00%)

BYND

Beyond Meat

$165.00

(0.00%)

ACB

Aurora Cannabis

$7.45

(0.00%)

SLB

Schlumberger

$38.25

(0.00%)

  • 21

    Jun

  • 21

    Jun

  • 19

    Jul

  • 27

    Aug

  • 13

    Nov

  • 21

    Jun

OPK Opko Health
$2.03

(0.00%)

02/28/19
BRRR
02/28/19
NO CHANGE
Target $5
BRRR
Outperform
Opko Health risk/reward still favors investment, says Barrington
Barrington analyst Michael Petusky lowered his price target for Opko Health to $5 from $7 after the company's Q4 revenue missed his estimate and Q1 guidance came in less than expected. The analyst, however, maintains an Outperform rating on the shares. He believes the risk/reward still favors investment.
04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
03/15/19
JEFF
03/15/19
UPGRADE
Target $5
JEFF
Buy
Opko Health assumed with a Buy from Hold at Jefferies
Jefferies analyst Maury Raycroft assumed coverage of Opko Health and upgraded the shares to Buy from Hold. The analyst raised his price target for the stock to $5 from $4. The company had a rough 2018, and though some headwinds may still be ahead, the "terrain gets a little smoother and more interesting in 2019." Raycroft tells investors in a research note. He sees the oxyntomodulin Phase IIb data by end of March as the next catalyst and does not believe the Street is focused on this program. Further, Rayaldee dialysis data by the end of 2019 "could put the drug on a different level commercially," says Raycroft.
05/08/19
BRRR
05/08/19
NO CHANGE
BRRR
Barrington keeps Outperform rating on Opko Health after Q1 report
Barrington analyst Michael Petusky maintained an Outperform rating and $5 price target on Opko Health after the company reported revenue that slightly exceeded the firm's estimate. However, the analyst noted that "despite an increase in prescriptions of 121% in Q1 versus the same period a year ago, Rayaldee revenue fell short in the quarter and guidance for Q2 revenue was also disappointing." While Petusky noted that there have been "more setbacks than positive surprises" over the last few years, he believes "the company still has many 'shots on goal' within both its current commercial portfolio as well as its product development pipeline."
TXMD TherapeuticsMD
$2.64

(0.00%)

06/11/19
JPMS
06/11/19
NO CHANGE
Target $6
JPMS
Overweight
TherapeuticsMD price target lowered to $6 from $8 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for TherapeuticsMD to $6 from $8 while keeping an Overweight rating on the shares. The analyst reduced his estimates after the company's 2019 guidance coming in below his expectations, reflecting "more challenging" gross-to-net dynamics for Imvexxy as well as a softer outlook for its vitamin business. However, Schott continues to see Imvexxy, Bijuva and Annovera as well positioned in their respective markets, which he believes should support "very strong uptake" over the next several years.
06/11/19
COWN
06/11/19
NO CHANGE
Target $9
COWN
Outperform
TherapeuticsMD price target lowered to $9 from $16 at Cowen
Cowen analyst Ken Cacciatore lowered his price target on TherapeuticsMD to $9 from $16 following its analyst day meeting. The company provided initial 2019 revenue projections for Imvexxy, Bijuva, and Annovera, which were modestly below expectations. Despite the shortfall, he still believes the products are sufficiently differentiated and the company is well capitalized so that it can reach profitability in the second half of 2021. Cacciatore maintained his Outperform rating on TherapeuticsMD shares.
06/11/19
OPCO
06/11/19
NO CHANGE
OPCO
TherapeuticsMD price target lowered to $10 from $13 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target on TherapeuticsMD to $10 from $13, and his FY19 sales estimates to $25.9M from $32.9M, after the company provided revenue guidance below consensus. Olson, however, kept an Outperform rating on the company based on the potential for TherapeuticsMD to "successfully penetrate and expand the market for treatment of menopausal symptoms" with its two products, Imvexxy and Bijuva.
06/12/19
CANT
06/12/19
NO CHANGE
Target $13
CANT
Overweight
TherapeuticsMD price target lowered to $13 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for TherapeuticsMD to $13 from $27, driven by multiple contraction, given increasing headwinds from macro factors. The analyst reiterates an Overweight rating on the shares.
GOLD Barrick Gold
$15.32

(0.00%)

04/10/19
DBAB
04/10/19
DOWNGRADE
Target $10
DBAB
Hold
Ryerson downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Ryerson to Hold from Buy and lowered his price target for the shares to $10 from $12. The analyst increased his precious metal exposure by upgrading both Barrick Gold (GOLD) and Pan American Silver (PAAS), but he's "not outright positive" on the Metals & Mining sector. While the analyst is still cautious on the stability of conditions in China, he notes there has been an improvement in growth conditions and "some strides" towards a trade deal with the U.S.
05/23/19
SBSH
05/23/19
NO CHANGE
Target $12.5
SBSH
Neutral
Citi upgrades Newmont, downgrades Barrick on resumption of coverage
Citi analyst Alexander Hacking resumed coverage of Barrick Gold and downgraded the shares to Neutral from Buy while lowering his price target to $12.50 from $14. He also resumed coverage of Newmont Mining (NEM) and upgraded the shares to Buy from Neutral while raising his price target for the shares to $40 from $36. The gold sector remains challenged, but Newmont offers better value than Barrick, Hacking tells investors in a research note. After applying Barrick's 1.2 times multiple to Newmont's holdings in the joint venture assets, the analyst sees Newmont's other assets trading at only 0.76 times net asset value. This could be re-rated higher as the market starts to incorporate the joint venture into models, says Hacking.
04/10/19
DBAB
04/10/19
UPGRADE
Target $15
DBAB
Buy
Deutsche upgrades Barrick to Buy on more favorable gold view
Deutsche Bank analyst Chris Terry upgraded Barrick Gold to Buy from Hold and raised his price target for the shares to $15 from $12.75. The analyst cites valuation for the upgrade after his firm's increased its view on gold prices. Further, he believes cost-out opportunities, synergies in Nevada and potential divestment opportunities that could provide positive catalysts for Barrick shares.
05/23/19
SBSH
05/23/19
DOWNGRADE
SBSH
Neutral
Barrick Gold downgraded to Neutral from Buy at Citi
CGC Canopy Growth
$43.70

(0.00%)

06/21/19
PIPR
06/21/19
NO CHANGE
Target $60
PIPR
Overweight
Canopy Growth sales growth on track after Q4 results, says Piper Jaffray
Piper Jaffray analyst Michael Lavery says Canopy Growth reported fiscal Q4 net sales of C$94M, modestly below his C$97M estimate but ahead of the C$90M consensus estimate. The analyst considers Canopy's sales growth to be on track, and he expects growth to accelerate as industry-wide supply shortages subside and hemp-derived CBD products are commercialized in the U.S. Canopy continues to invest for growth, and positive adjusted EBITDA is not expected in the near-term, Lavery tells investors in a research note. He keeps an Overweight rating on the shares with a $60 price target.
06/05/19
STFL
06/05/19
INITIATION
STFL
Stifel initiates coverage of Canadian cannabis companies
Stifel analyst W. Andrew Carter initiated coverage of Canopy Growth (CGC) with a Buy rating and C$55 price target, Aurora Cannabis (ACB) with a Hold rating and C$10 price target, Cronos Group (CRON) with a Hold rating and C$18 price target, and Tilray (TLRY) with a Hold rating and $37 price target. The analyst is bullish on the growth prospects for the cannabis industry, especially through the Canadian Licensed Producers, or LPs. Carter sees these four companies as holding a lead in the legal Canadian market, and believes they represent the "best investable opportunities in a global cannabis industry" that the firm sees reaching $200B in value. The analyst calls Canopy Growth the best opportunity, citing "definitive category leadership, C$4B cash on hand offering significant optionality, and the best position to attack the $100B U.S. opportunity."
06/10/19
PIPR
06/10/19
NO CHANGE
PIPR
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
After Washington D.C. lobbyist Michael Esposito, who also works closely with President Trump's administration, spoke at his firm's conference, Piper Jaffray analyst Michael Lavery believes cannabis regulation could become a top 2020 election issue. By supporting cannabis, Trump may be able to incrementally broaden his appeal with swing voters without alienating his base, Esposito tells investors in a research note. Though Trump has indicated his willingness to support the STATES Act, his enthusiasm could depend on whether or not Elizabeth Warren, author of the bill, is his opponent, adds the analyst in a note titled "Handicapping US Legalization Outlook: Politics Are Complicated." And while Senate Majority Leader Mitch McConnell is a roadblock for legislation in the Senate, Trump could use executive orders between now and the election to show support for the industry, potentially relating to cannabis banking or medical research, says Lavery. The analyst has Overweight ratings on both Canopy Growth (CGC) and Tilray (TLRY). Other names in the space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Zynerba (ZYNE).
06/10/19
COMP
06/10/19
INITIATION
COMP
Neutral
Canopy Growth initiated with a Neutral at Compass Point
Compass Point analyst Rommel Dionsio started Canopy Growth with a Neutral rating.
ORCL Oracle
$57.02

(0.00%)

06/20/19
RAJA
06/20/19
NO CHANGE
Target $61
RAJA
Outperform
Oracle price target raised to $62 from $57 at Raymond James
Raymond James analyst Michael Turits raised his price target for Oracle to $61 from $57 following a "strong" 4Q report with revenue upside driven by database/middleware license, guidance for CC revenue acceleration into 2020 reiterated, and double digit 2020 EPS growth guidance established. The analyst reiterates an Outperform rating on the shares.
06/20/19
WBLR
06/20/19
NO CHANGE
WBLR
Market Perform
Oracle Q4 solid, 'but too early to call a trend,' says William Blair
William Blair analyst Jason Ader says that while Oracle last night reported "solid" fiscal Q4 results, it is "too early to call a trend." It is too soon to determine if Oracle is turning a corner, especially as its Q1 revenue guidance was below consensus, Ader tells investors in a research note. The analyst, who sees "some light at the end of the tunnel for the first time in a while," keeps a Market Perform rating on Oracle shares.
06/20/19
MSCO
06/20/19
NO CHANGE
Target $59
MSCO
Equal Weight
Oracle database results likely reopen growth debate, says Morgan Stanley
Morgan Stanley analyst Keith Weiss said Oracle's strong rebound in license revenues in Q4, driven by strong sales of database and database options, will likely reopen the debate about the company's growth potential. However, he thinks it is too soon to call one quarter a trend given that his survey work has pointed to weak spending intentions for Oracle's database, with IT budgets moving away from the company amid an industry shift to the cloud. Weiss keeps an Equal Weight rating on Oracle with a $59 price target.
06/20/19
WELS
06/20/19
NO CHANGE
Target $65
WELS
Outperform
Oracle price target raised to $65 from $60 at Wells Fargo
Wells Fargo analyst Philip Winslow raised his price target for Oracle to $65 from $60 after the company's Q4 results exceeded consensus expectations for revenue, operating margin, and EPS driven by strength in its database offerings along with particularly notable traction in add-on options related to its Autonomous Database. The analyst continues to view Oracle's Autonomous Database as differentiated and well-positioned and believes in its ability to lower labor cost and error rates while driving improved productivity with lower deployment effort. Winslow reiterates an Outperform rating on the shares.
LULU Lululemon
$186.33

(0.00%)

06/13/19
JEFF
06/13/19
NO CHANGE
Target $175
JEFF
Hold
Lululemon price target raised to $175 from $156 at Jefferies
Jefferies analyst Randal Konik raised his price target for Lululemon Athletica to $175 from $156 following the company's Q1 results. Lululemon posted strong traffic, strong new and existing customer growth as well as pricing power, Konik tells investors in a research note. He admits he downgraded the shares "way too early" and keeps a Hold rating on the name despite raising his numbers.
06/13/19
DADA
06/13/19
NO CHANGE
Target $180
DADA
Neutral
Lululemon price target raised to $180 from $155 at DA Davidson
DA Davidson analyst John Morris raised his price target on Lululemon to $180 after its Q1 earnings beat driven by better than expected comps and gross margins that were "slightly offset" by the company's planned SG&A increases. The analyst notes that the company is setting up for "growth-driving investments" in Q2 and beyond while raising his FY19 EPS view to $4.77 from $4.63, but also points to the headwinds of tougher comps of 19%, 18%, and 17% in Q2, Q3, and Q4 of 2019. Morris keeps his Neutral rating on Lululemon and adds that as gross margins approach their historically high levels, upside for further expansion diminishes.
06/13/19
NEED
06/13/19
NO CHANGE
NEED
Hold
Needham looking for better entry point on Lululemon
Needham analyst Rick Patel kept his Hold rating on Lululemon but said he is looking for a "better entry opportunity" on the stock after its "strong" Q1 results, saying the quarter marked a "continuation" of the company's execution across products, channels, and geographies. The analyst notes that although the magnitude of the earnings beat was relatively smaller, the results were "favorable" against the backdrop of a challenging retail environment. Patel believes that Lululemon can continue to generate strong comps, even though its gross margin expansion will slow as the company "laps significant product cost-related improvements."
06/14/19
BERN
06/14/19
NO CHANGE
BERN
Lululemon valuation can be sustained with SSS in double digits, says Bernstein
Bernstein analyst Jamie Merriman maintained 2019 EPS estimate of $4.62 following lululemon's Q1 results, and raised her 2020 EPS estimate to $5.60 due to stronger than expected direct to consumer growth in Q1 driving increased topline. In a research note to investors, Merriman says that while she believes lululemon's valuation can be sustained as long as total comp sales growth continues in the double digits, she struggles to find room for upside in the medium to long term.
PCG PG&E
$23.59

(0.00%)

06/20/19
BOFA
06/20/19
UPGRADE
Target $13
BOFA
Neutral
Bloom Energy upgraded to Neutral from Underperform at BofA/Merrill
BofA Merrill Lynch analyst Julien Dumoulin-Smith upgraded Bloom Energy (BE) to Neutral from Underperform as he sees shares being supported by shifting trends in its core California markets amid proactive deenergizations by PG&E (PCG) as well as more broadly across the U.S. East Coast. Following a call with Generac (GNRC) that pointed to a meaningful inflection in California customers' demand for stand-by generators, the analyst expects increased demand for Bloom's micro-grid solution, he said. He also thinks the increased focus and need for reliability with the 5G build-out for major telecom companies will support demand for Bloom products, the analyst added. He has a $13 price target on Bloom Energy shares.
06/21/19
MSCO
06/21/19
NO CHANGE
MSCO
Equal Weight
California proposal only a 'partial fix' for PG&E, says Morgan Stanley
After Bloomberg reported yesterday that California Governor Gavin Newsom is encouraging the state's legislature to adopt several of the Wildfire Commission's recommendations, including a liquidity fund seeded by at least $10B in Department of Water Resources bonds and $7.5B in utility equity contributions, Morgan Stanley analyst Stephen Byrd said he thinks the plan outlined in the report is only a "partial fix" and would not be satisfactory for large institutional equity investors, for whom some type of cap on future liability is critical. The analyst, who thinks long-term investors will likely require more steps than those outlined in the Bloomberg report before buying PG&E shares, keeps an Equal Weight rating on the stock.
06/06/19
SBSH
06/06/19
NO CHANGE
SBSH
Buy
Citi found CA Assembly Utilities Committee hearing positive for PG&E
Citi analyst Praful Mehta found increased acknowledgement by a number of members that wildfire costs do need to be socialized across a number of group at yesterday's California Assembly Utilities Committee hearing. This acknowledgement, rather than a singular focus on holding the utility accountable, is a "step towards a constructive solution," Mehta tells investors in a research note. He continues to believe legislation will be passed this session and that it will "follow the path of least resistance." Mehta views the hearing as positive and remains constructive on shares of PG&E (PCG) and Edison International (EIX). He keeps a Buy rating on PG&E with a $33 price target.
04/24/19
BOFA
04/24/19
NO CHANGE
BOFA
PG&E deal talks report could drive renewed interest, says BofA/Merrill
BofA Merrill Lynch analyst Julien Dumoulin-Smith noted that SparkSpread reported that Berkshire Hathaway Energy (BRK.A) was in talks to acquire bankrupt PG&E (PCG). However, CNBC subsequently reported that Berkshire had no interest, citing direct conversations with Warren Buffett, and a spokesperson also noted the company is not in talks with PG&E, noted the analyst. Still, he thinks headlines regarding the Berkshire interest could help drive renewed interest in PG&E from other large-cap entities, adding that "for all of the same reasons why we see credibility to a potential Berkshire bid, much of the same applies to any other large buyer." Dumoulin-Smith keeps No Rating on PG&E shares given ongoing Chapter 11 proceedings.
BYND Beyond Meat
$165.00

(0.00%)

06/13/19
FBCO
06/13/19
NO CHANGE
FBCO
Tyson plant-based launch not big threat to Beyond Meat, says Credit Suisse
Credit Suisse analyst Robert Moskow says this morning's launch of plant-based chicken nuggets and patties and hybrid beef-plant burgers and sausages supports his positive view on Tyson Foods (TSN). Perdue and Hormel Foods (HRL) have also signaled similar intentions to pursue hybrid meats, Moskow tells investors in a research note. The analyst, however, does not view Tyson's hybrid burgers as a major threat to Beyond Meat (BYND). Beyond's burger products are "more revolutionary and broader" in terms of potential consumer appeal, contends Moskow. Although competing hybrid burgers offer less saturated fat than the 100% plant-based products from Beyond and Impossible, "they simply don't taste as good in our experience," writes the analyst. Shares of Beyond Meat are down $1.04 to $140.93 in early trading while Tyson Foods is up $1.92 to $83.82.
06/11/19
06/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Underweight from Neutral at Atlantic Equities with analyst John Heagerty. 2. Symantec (SYMC) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying his recent survey of Chief Security Officers points to Symantec losing share in endpoint security and web security, which poses risk to its revenue growth guidance. 3. Shell Midstream (SHLX) downgraded to Underperform from Neutral at Credit Suisse with analyst Spiro Dounis noting that lower than anticipated re-contracted Zydeco pipeline rates result in a more challenged financial outlook that likely requires the Sponsor to remain accommodative. 4. Beyond Meat (BYND) downgraded to Neutral from Overweight at JPMorgan analyst Ken Goldman saying the stock at around $168 "requires assumptions we are not yet comfortable with." 5. Denny's (DENN) downgraded to Hold from Buy at Maxim with analyst Stephen Anderson saying that he remains "constructive" on the company's continued "brand rejuvenation" and refranchising program, modeling earning growth accelerating to 31% in 2020 from the projected 9% this year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
06/12/19
BERN
06/12/19
DOWNGRADE
Target $123
BERN
Market Perform
Beyond Meat downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Alexia Howard downgraded Beyond Meat to Market Perform from Outperform with a price target of $123. . The downgrade is due to "valuation considerations as the stock has traded in a highly volatile manner since its IPO likely due to its limited public float," Howard tells investors in a research note. The analyst now sees limited upside for the stock. Beyond Meat closed yesterday down 25%, or $42.06, to $126.04 after JPMorgan analyst Ken Goldman downgraded the shares on valuation concerns
06/12/19
06/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cisco (CSCO) downgraded to Market Perform from Outperform at William Blair with analyst Jason Ader saying he sees "signs of tightening demand" across IT infrastructure, which he believes could pressure growth in Cisco's fiscal 2020, "especially when compared against unusually strong demand in fiscal 2019." 2. Manpower (MAN) downgraded to Neutral from Outperform at Credit Suisse. 3. Dave & Buster's (PLAY) downgraded to Hold from Buy at Gordon Haskett and SunTrust, as well as to Market Perform from Outperform at Wells Fargo. 4. Amcor (AMCR) reinstated with a Sell from Neutral at Goldman Sachs with analyst Brian Maguire saying Bemis's earnings growth "has not proven to be as resilient in recent years." 5. Beyond Meat (BYND) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard saying "valuation considerations as the stock has traded in a highly volatile manner since its IPO likely due to its limited public float." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ACB Aurora Cannabis
$7.45

(0.00%)

06/05/19
STFL
06/05/19
INITIATION
STFL
Hold
Stifel starts Aurora at Hold on 'more bearish outlook' outside Canada
Stifel analyst W. Andrew Carter initiated coverage of Aurora Cannabis with a Hold rating and C$10 price target. The analyst cautious on the shares given his "more bearish outlook" for the development of the global medical-use opportunities outside of Germany and Canada. He believes these are required to support Aurora's consensus revenue estimates. Further, the lack of "meaningful avenues for attacking" the U.S., and the risk around meaningful sector underperformance, could challenge Aurora's funding needs to continue to build out its infrastructure and positioning in the global market, Carter tells investors in a research note.
06/05/19
STFL
06/05/19
INITIATION
STFL
Hold
Aurora Cannabis initiated with a Hold at Stifel
Stifel analyst W. Andrew Carter initiated Aurora Cannabis with a Hold rating and C$10 price target.
SLB Schlumberger
$38.25

(0.00%)

04/22/19
04/22/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from In Line at Evercore ISI with analyst Arndt Ellinghorst citing his more cautious view on demand for its vehicles, in particular the recent "severe decline" in demand for the Model S and Model X. 2. Schlumberger (SLB) downgraded to Sell from Hold at Tudor Pickering. 3. Dunkin' Brands (DNKN) downgraded to Hold from Buy at Maxim. 4. D.R. Horton (DHI) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Jade Rahmani citing valuation. 5. Occidental Petroleum (OXY) downgraded to Neutral from Buy at Mizuho with analyst Paul Sankey saying reports of Occidental bidding for Anadarko (APC) are "well outside" his "prior understanding of company strategy." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/23/19
RHCO
04/23/19
NO CHANGE
Target $53
RHCO
Buy
Schlumberger price target lowered to $53 from $60 at SunTrust
SunTrust analyst Ken Sill lowered his price target on Schlumberger to $53 after its Q1 results, saying that while its international growth is offsetting a "sluggish" North America, the back half of the year also has "low visibility". The analyst adds that his new implied multiple of 11.1-times enterprise value to expected FY20 EBITDA is above the average forward multiple of 10.6-times over the past 10 years, it is also below the longer term average annual high of 12.7-times. Longer term, Sill keeps his Buy rating on Schlumberger, stating that its increased near-term leverage to North American activity should lead to sustainable long-term growth.
06/07/19
STFL
06/07/19
UPGRADE
Target $50
STFL
Buy
Schlumberger upgraded to Buy from Hold at Stifel
Stifel analyst Stephen Gengaro upgraded Schlumberger to Buy from Hold with an unchanged price target of $50. The company is generating "solid" free cash flow and the stock's risk/reward is "compelling" at current levels, Gengaro tells investors in a research note. Further, the company's $2.00 per share annual dividend is "safe" and investors are getting "paid to wait," adds the analyst. He believes Schlumberger is well positioned to benefit as activity rises outside North America.
05/15/19
RBCM
05/15/19
NO CHANGE
Target $51
RBCM
Outperform
Schlumberger price target lowered to $51 from $58 at RBC Capital
RBC Capital analyst Kurt Hallead lowered his price target on Schlumberger to $51 to reflect the "fine tuning" of corporate expense estimate to percentage of revenue from previously assumed flat levels, also lowering his FY19 and FY20 EPS view by 3c and 9c to $1.55 and $2.05 as a result. The analyst maintains his Outperform rating however, saying the stock remains a "core through-cycle holding" for large-cap energy investors and anticipating an improvement in the company's international market dynamics.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$19.94

0.16 (0.81%)

17:57
08/16/19
08/16
17:57
08/16/19
17:57
Hot Stocks
Breaking Hot Stocks news story on Wendy's »

Trian Fund lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRY

Berry Petroleum

$8.59

0.39 (4.76%)

17:54
08/16/19
08/16
17:54
08/16/19
17:54
Syndicate
Breaking Syndicate news story on Berry Petroleum »

Berry Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSWI

CSW Industrials

$70.20

1.92 (2.81%)

17:52
08/16/19
08/16
17:52
08/16/19
17:52
Hot Stocks
CSW Industrials CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$3.03

0.135 (4.66%)

17:49
08/16/19
08/16
17:49
08/16/19
17:49
Hot Stocks
Oasis Petroleum CEO buys 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EE

El Paso Electric

$66.41

0.005 (0.01%)

17:45
08/16/19
08/16
17:45
08/16/19
17:45
Hot Stocks
El Paso Electric director Wertheimer sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$165.07

2.81 (1.73%)

17:42
08/16/19
08/16
17:42
08/16/19
17:42
Hot Stocks
Honeywell CEO sells 7.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBRX

Moleculin Biotech

$1.08

0.01 (0.93%)

17:37
08/16/19
08/16
17:37
08/16/19
17:37
Earnings
Moleculin Biotech reports Q2 EPS (3c), two estimates (10c) »

CFO Jonathan Foster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.